{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"41.6","value":"247"}]}],"title":"Post-dose Cycle 1 (n=201)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.9","value":"227"}]}],"title":"Pre-dose Cycle 2 (n=198)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.5","value":"587"}]}],"title":"Post-dose Cycle 2 (n=197)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"68.7","value":"165"}]}],"title":"Pre-dose Cycle 3 (n=193)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.7","value":"527"}]}],"title":"Post-dose Cycle 3 (n=192)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"74.3","value":"156"}]}],"title":"Pre-dose Cycle 4 (n=191)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"41.0","value":"535"}]}],"title":"Post-dose Cycle 4 (n=189)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"72.4","value":"163"}]}],"title":"Pre-dose Cycle 5 (n=185)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.1","value":"534"}]}],"title":"Post-dose Cycle 5 (n=181)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"69.0","value":"181"}]}],"title":"Pre-dose Cycle 6 (n=185)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.6","value":"525"}]}],"title":"Post-dose Cycle 6 (n=183)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"}],"units":"Participants"}],"description":"Blood samples were collected from all patients allocated to the GClb treatment arm pre- and post-dose Day 1 of Cycles 1 to 6 and were sent to a laboratory. The concentration of obinutzumab in serum was determined using a validated enzyme-linked immunosorbent assay (ELISA) and was reported in micrograms/milliliter (μg/mL).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \\[First infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).","id":"OG000","title":"Obinutuzumab + Chlorambucil (GClb)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK population includes all participants with PK data available at the given time-point.","reportingStatus":"POSTED","timeFrame":"Pre- and post-dose sampling on day 1 of cycles 1-6 (Up to 26.8 months)","title":"Pharmacokinetics of Obinutuzumab (RO5072759) in Combination With Chlorambucil (Clb)","type":"SECONDARY","unitOfMeasure":"μg/mL"}